证券记录 · 已归档季度
EW
Edwards Lifesciences Corporation · Healthcare · Medical - Devices
19被追踪持有人
+1Δ持有人
77.58M持有股份
$5.12B报告持仓市值
+2新建仓位
−1清仓
动量输入（同类管理人）：
持有人广度 +5.6% ·
股份流向 +29.1% ·
净新建仓位 +5.3%
· 公式
广泛增持：持股数量上升，持有人数量增加
所有持股数据：仅限已追踪的 13F 管理人，普通股持仓，报告期 Q3 2024
持股变化趋势
| 季度 | 持有人 | Δ | 股份 | 报告持仓市值 | 新增 | 清仓 |
|---|---|---|---|---|---|---|
| Q3 2026 | 4 | 0 | 14.87M | $1.28B | n/a | −2 |
| Q2 2026 | 163 | -6 | 423.46M | $38.23B | +2 | −9 |
| Q1 2026 | 173 | +2 | 408.99M | $32.75B | +6 | −5 |
| Q4 2025 | 170 | 0 | 441.50M | $37.63B | +2 | −1 |
| Q3 2025 | 24 | -1 | 280.60M | $21.82B | +1 | −3 |
| Q2 2025 | 23 | 0 | 232.09M | $18.15B | n/a | n/a |
| Q1 2025 | 20 | -1 | 112.98M | $8.18B | n/a | −1 |
| Q4 2024 | 21 | +1 | 116.40M | $8.61B | +1 | n/a |
| Q3 2024 | 19 | +1 | 77.58M | $5.12B | +2 | −1 |
| Q2 2024 | 18 | n/a | 60.09M | $5.55B | n/a | n/a |
持有人 · Q3 2024
| # | 管理人 | 股份 | Δ股份 | 价值 | 其权重 | 持有 | ||
|---|---|---|---|---|---|---|---|---|
| 1 | Wellington Management ✦ | 31.53M | +86.3% | $2.08B | 0.4% | ▲ Add | 2 | SEC ↗ ×9 |
| 2 | Geode Capital Management ✦ (被动) | 13.52M | +2.1% | $889.05M | 0.1% | ▲ Add | 2 | SEC ↗ ×2 |
| 3 | Fisher Asset Management ✦ | 9.08M | +9.8% | $599.08M | 0.2% | ▲ Add | 2 | SEC ↗ |
| 4 | Norges Bank ✦ (被动) | 7.22M | -15.4% | $476.46M | 0.1% | ▼ Trim | 2 | SEC ↗ |
| 5 | Marshall Wace ✦ | 3.73M | +4900.6% | $246.39M | 0.3% | ▲ Add | 2 | SEC ↗ ×2 |
| 6 | T. Rowe Price ✦ | 3.54M | -51.7% | $233.72M | 0.0% | ▼ Trim | 2 | SEC ↗ ×2 |
| 7 | Citadel Advisors ✦ | 1.99M | +218.9% | $131.42M | 0.1% | ▲ Add | 2 | SEC ↗ ×2 |
| 8 | PRIMECAP Management ✦ | 1.78M | -1.4% | $117.77M | 0.1% | ▼ Trim | 2 | SEC ↗ |
| 9 | Renaissance Technologies ✦ | 1.22M | 新增 | $80.62M | 0.1% | New | 1 | SEC ↗ |
| 10 | Millennium Management ✦ | 1.14M | +117.7% | $75.30M | 0.1% | ▲ Add | 2 | SEC ↗ |
| 11 | D. E. Shaw & Co. ✦ | 983.22K | +996.7% | $64.88M | 0.1% | ▲ Add | 2 | SEC ↗ ×2 |
| 12 | Adage Capital Partners ✦ | 834.75K | +28.5% | $55.09M | 0.1% | ▲ Add | 2 | SEC ↗ |
| 13 | Soros Fund Management ✦ | 300.00K | 新增 | $19.80M | 0.6% | New | 1 | SEC ↗ |
| 14 | Baillie Gifford ✦ | 208.70K | -40.8% | $13.77M | 0.0% | ▼ Trim | 2 | SEC ↗ ×4 |
| 15 | Bridgewater Associates ✦ | 165.45K | -68.2% | $10.92M | 0.1% | ▼ Trim | 2 | SEC ↗ |
| 16 | AQR Capital Management ✦ | 145.58K | -52.9% | $9.61M | 0.0% | ▼ Trim | 2 | SEC ↗ ×3 |
| 17 | Arrowstreet Capital ✦ | 89.78K | -60.1% | $5.92M | 0.0% | ▼ Trim | 2 | SEC ↗ |
| 18 | Two Sigma Investments ✦ | 74.57K | -51.0% | $4.92M | 0.0% | ▼ Trim | 2 | SEC ↗ |
| 19 | Gotham Asset Management ✦ | 7.98K | -32.7% | $526,534 | 0.0% | ▼ Trim | 2 | SEC ↗ |
"持仓权重"指该仓位占该管理人13F申报股票组合市值的比例，即持仓信心指标。✦ = 精选管理人。
新增买入方
| Renaissance Technologies | $80.62M | 0.1% |
| Soros Fund Management | $19.80M | 0.6% |
已清仓
| Point72 Asset Management | $41.03M | 曾为 0.1% |
全市场背景: 涵盖所有13F申报机构（SEC结构化数据， Q1 2026): 4 持有人, 229.24K 股份, $319,498 已申报. 这是与上方被追踪全域数据不同的较早期间，两者从不混用。
常见共同持仓
持有该证券的受追踪机构最常同时持有的其他证券：基于共同持有计数，而非基本面关联。
公开市场买入 (P)
在我们的覆盖窗口内无内部人士公开市场买入记录。
公开市场卖出 (S)
Oct 08
Lippis Daniel J.
Officer · 619 股 · $53,017
Sep 11
Lippis Daniel J.
Officer · 619 股 · $54,169
Aug 31
Dahl Andrew M.
Officer · 544 股 · $49,534
Aug 28
Bruls Annette
Officer · 2.64K 股 · $237,907
Aug 26
Markowitz Wayne
Officer · 1.24K 股 · $113,417
Aug 26
Chopra Daveen
Officer · 1.15K 股 · $105,893
Aug 26
Chopra Daveen
Officer · 30.65K 股 · $2.79M
Aug 11
Lippis Daniel J.
Officer · 619 股 · $56,967
授予、行权及税务代扣代缴在本平台均不计入买入或卖出。 方法论
数据来源: 持股数据来源于已解析的13F普通股持仓（被追踪范围，变动对比集）；内部人行为来自Form 3/4/5；重大持股来自Schedule 13D/13G；所有文件均链接至SEC EDGAR原始申报。
报告期: Q3 2024 ·
方法论 ·
通过API获取此数据